|Bid||29.00 x 1800|
|Ask||39.50 x 1200|
|Day's Range||37.00 - 37.64|
|52 Week Range||24.79 - 39.44|
|Beta (3Y Monthly)||0.96|
|PE Ratio (TTM)||76.81|
|Earnings Date||Jan 30, 2019 - Feb 4, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||42.41|
Medtronic (MDT) reported net revenues of $7.5 billion in the second quarter of fiscal 2019 compared to $7.1 billion in the second quarter of fiscal 2018, reflecting 6% YoY growth.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech stocks hitting 52-week highs on Dec. 11) Imprimis Pharmaceuticals Inc (NASDAQ: IMMY ) OvaScience ...
Delaware Court Rules Edwards Lifesciences Infringes Boston Scientific Patent MARLBOROUGH, Mass. , Dec. 11, 2018 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced that a jury in ...
Shire is a pharmaceutical company, with a wide range of products approved for use around the world. Some of the more familiar drugs the company produces include Adderall, prescribed for adult ADD, and Pentasa, used to treat Crohn's and other inflammatory bowel diseases. The company possesses both strength and weakness, and both are evident in the most recent quarterly report.
Why Has General Electric Stock Struggled in 2018? The Healthcare segment is the fourth-largest contributor to General Electric’s total revenues. As part of the company’s major restructuring plan in June, General Electric intends to spin off the segment and turn it into a standalone entity.
Maple Grove-based Francis Medical will put the funding toward clinical trials as it prepares to roughly double its 10-person staff over the next year.
At Insider Monkey we follow around 700 of the best-performing investors and even though many of them lost money in the last couple of months (70% of hedge funds lost money in October whereas S&P 500 ETF lost about 7%), the history teaches us that over the long-run they still manage to beat the market, […]
NEW YORK, Dec. 07, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
After a stellar ride from $25.32 on January 4, 2018, to $39.04 on October 2, Boston Scientific stock (BSX) has fluctuated in the past month. From $35.38 on October 29, 2018, Boston Scientific stock rose to $38.60 on November 9, 2018. Boston Scientific’s revenue grew by 7.7% from $2.22 billion in the third quarter of 2017 to $2.39 billion in the third quarter of 2018.
Boston Scientific’s stock moved 5.17% lower Tuesday, to close the day at $36.52. The stock recorded a trading volume of 8,966,181 shares, which was above its three months average volume of 7,581,259 shares. In the last year, Boston Scientific’s shares have traded in a range of 24.54 - 39.44.
MARLBOROUGH, Mass. , Dec. 3, 2018 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will participate in the 2018 BMO Capital Markets Prescriptions for Success Healthcare Conference on Wednesday, ...
Boston Scientific (BSX) closed at $37.67 in the latest trading session, marking a +1.7% move from the prior day.
In November 2018, of the total 15 analysts covering Align Technology (ALGN), 13 analysts have given Align stock a “buy” or higher rating, and two analysts have given it a “hold” rating. The mean rating for Align Technology stock is 1.67 with a target price of $317.36, implying an upside potential of 43.8% over Align Technology’s closing price of $220.71 on November 27, 2018.
Align Technology (ALGN) is focused on establishing its Invisalign clear aligners as the standard method for treating malocclusion and establishing its iTero intraoral scanner as the scanning device of choice for 3D digital scans.
For fiscal 2018 and 2019, Align Technology’s gross margins are expected at 73.97% and 73.69%, respectively, as compared with gross margins of 75.81% for fiscal 2017. In comparison, the fiscal 2018 gross margins of peers Abbott Laboratories (ABT), Boston Scientific (BSX), and Edwards Lifesciences (EW) are expected at 59.29%, 72.08%, and 74.83%, respectively.
In November, among the 22 analysts covering Edwards Lifesciences (EW), 13 recommended a “buy” or higher rating, seven recommended a “hold” rating, and two recommended a “sell” or lower rating. The mean rating for Edwards Lifesciences stock is 2.32 with a target price of $161.53, which implies an upside potential of 4.5% over Edwards Lifesciences’ closing price of $154.52 on November 27.
Boston Scientific (BSX) stock rose from $24.79 at the close of market on December 29, 2017, to $34.80 at the close of market on November 23, 2018, reflecting a rise of ~40% year-to-date. On November 23, Boston Scientific stock closed at $34.80, a ~42% rise from its 52-week low of $24.54 on December 6, 2017.
A strong operational performance and steady uptick in Edwards Lifesciences’ (EW) stock price has kept investors interested in the stock in 2018. In this series, we’ll discuss Edwards Lifesciences’ financials, segmental performance, analysts’ views on the stock, and the company’s valuation metrics. Edwards Lifesciences is a leader in patient-focused solutions for structural heart disease and critical care monitoring.
Edwards Lifesciences’ (EW) cost of sales increased from $213.3 million in the third quarter of 2017 to $224.9 million in the third quarter. The company’s gross profit grew from $608.2 million in the third quarter of 2017 to $681.7 million in the third quarter due to the improved product mix.
Jim Cramer fires off his answers to callers' stock questions, including a query on a regional banking play.
MARLBOROUGH, Mass. , Nov. 27, 2018 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will participate in Citi's 2018 Global Healthcare Conference on Thursday, December 6, 2018 in New York City ...
Desperate for relief after years of agony, Jim Taft listened intently as his pain management doctor described a medical device that could change his life. Taft's stimulator failed soon after it was surgically implanted. For years, medical device companies and doctors have touted spinal-cord stimulators as a panacea for millions of patients suffering from a wide range of pain disorders, making them one of the fastest-growing products in the $400 billion medical device industry.